Activity of Ponatinib and Vitamin K2 Against Myelodysplastic Syndrome and Acute Myeloid Leukemia Cells
{{output}}
Background/aim: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy often characterized by poor response to conventional therapies and frequent relapse. Ponatinib, a third-generation tyrosine kinase inhibitor, ... ...
